Date: Tuesday, 14 June 2016, 10 am (Manila Time)


Abstract

Understanding the influences of molecular alterations on pharmacological responses in the omic sense is at the fore of the effort to make oncology treatments more effective and specific. At present, however, this remains a field in its infancy. The NCI-60 cancerous cell lines provide a premier set of databases and tools for systems molecular pharmacological studies. This is due to the availability of both the robust, high-quality activity profiles generated by the Developmental Therapeutics Program (https://dtp.cancer.gov), and the panoply of molecular and phenotypic information available. The CellMiner web-application (http://discover.nci.nih.gov/cellminer) provides the user access to both of these. Activity data is currently available for 20,861 compounds, including 158 Food and Drug Administration (FDA)-approved, 77 clinical trial, and 416 known mechanism-of-action drugs. The molecular data includes transcript expression for 25,772 genes, genetic variants for 16,568 genes, transcript expression for 360 microRNAs, protein levels for 94 genes, DNA copy number (from aCGH) for 23,413 genes, and soon DNA methylation levels for 17,559 genes. “Cell line signatures” are provided for each of these data types, facilitating their comparison. The “Pattern comparisons” tool compares any input pattern of interest to 71,289 activity, molecular and phenotypic patterns (For CellMiner 1.6). Here we present our CellMiner databases, tools, and examples of molecular pharmacological data integration, including translationally relevant results.


william_reinholdDr. William Reinhold

Head, Genomics and Bioinformatics Group,
DTB, CCR, NCI, NIH, Bethesda, MD 20892 USA
http://discover.nci.nih.gov/cellminer

About the Speaker
Brief Curriculum Vitae
Publications

Download Slides: Set 1 | Set 2


TO JOIN THIS WEBINAR: Send an email to: [email protected] and ask for the weblink.